|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Martin Welschof Ph.D.||Pres & CEO||4,75M||N/D||1961|
|Mr. Stefan Ericsson M.B.A.||Chief Financial Officer||N/D||N/D||1963|
|Ms. Marie Moores M.Sc., R.G.N.||Chief Operating Officer||N/D||N/D||N/D|
|Mr. Kristoffer Rudenholm Hansson||Sr. VP of Technical Operations||N/D||N/D||1974|
|Mr. Björn Frendéus||Chief Scientific Officer||N/D||N/D||1973|
|Ms. Cecilia Hofvander||Sr. Director of Investor Relations||N/D||N/D||1967|
|Dr. Andres McAllister||Chief Medical Officer||N/D||N/D||1956|
|Ms. Ingrid Teige||Head of Preclinical Research||N/D||N/D||N/D|
|Ms. Sylvie Ryckebusch||Chief Bus. Officer||N/D||N/D||N/D|
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
L'ISS Governance QualityScore di BioInvent International AB (publ) al 1 dicembre 2022 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 8.